Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve (1)The Audited Financial Results ....
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt has informed the stock exchanges that its Board of Directors will meet on 29th May 2025. The Board will consider and approve the audited financial results (standalone and consolidated) for Q4 and the full financial year ended 31st March 2025. Additionally, the Board will discuss a proposal to raise funds through various instruments such as equity shares, Global Depository Receipts (GDRs), American Depository Receipts (ADRs), Foreign Currency Convertible Bonds (FCCBs), and other convertible or non-convertible securities, potentially in multiple tranches via public, private, qualified institutional placement (QIP), or preferential allotment routes. The final fund raise will require shareholder approval at the upcoming Annual General Meeting. The trading window for dealing in shares remains closed until 48 hours after the results are declared.
Investors should watch for two key outcomes on 29th May: the FY25 results (which will reveal the company's full-year financial health) and the size and structure of the proposed fund raise, which could lead to dilution of existing shareholders' stake depending on the instrument and amount chosen.